Cite
Alkelai A, Greenbaum L, Docherty AR, et al. The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. Mol Psychiatry. 2021;doi: 10.1038/s41380-021-01383-9.
Alkelai, A., Greenbaum, L., Docherty, A. R., Shabalin, A. A., Povysil, G., Malakar, A., Hughes, D., Delaney, S. L., Peabody, E. P., McNamara, J., Gelfman, S., Baugh, E. H., Zoghbi, A. W., Harms, M. B., Hwang, H. S., Grossman-Jonish, A., Aggarwal, V., Heinzen, E. L., Jobanputra, V., Pulver, A. E., Lerer, B., & Goldstein, D. B. (2021). The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. Molecular psychiatry, . https://doi.org/10.1038/s41380-021-01383-9
Alkelai, Anna, et al. "The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders." Molecular psychiatry vol. (2021). doi: https://doi.org/10.1038/s41380-021-01383-9
Alkelai A, Greenbaum L, Docherty AR, Shabalin AA, Povysil G, Malakar A, Hughes D, Delaney SL, Peabody EP, McNamara J, Gelfman S, Baugh EH, Zoghbi AW, Harms MB, Hwang HS, Grossman-Jonish A, Aggarwal V, Heinzen EL, Jobanputra V, Pulver AE, Lerer B, Goldstein DB. The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. Mol Psychiatry. 2021 Nov 19; doi: 10.1038/s41380-021-01383-9. Epub 2021 Nov 19. PMID: 34799694.
Copy
Download .nbib